173 related articles for article (PubMed ID: 27910741)
1. Topotecan Liposomes: A Visit from a Molecular to a Therapeutic Platform.
Saraf S; Jain A; Hurkat P; Jain SK
Crit Rev Ther Drug Carrier Syst; 2016; 33(5):401-432. PubMed ID: 27910741
[TBL] [Abstract][Full Text] [Related]
2. The role of pH and ring-opening hydrolysis kinetics on liposomal release of topotecan.
Fugit KD; Anderson BD
J Control Release; 2014 Jan; 174():88-97. PubMed ID: 24231406
[TBL] [Abstract][Full Text] [Related]
3. Revisiting the nanoformulation design approach for effective delivery of topotecan in its stable form: an appraisal of its in vitro Behavior and tumor amelioration potential.
Padhi S; Mirza MA; Verma D; Khuroo T; Panda AK; Talegaonkar S; Khar RK; Iqbal Z
Drug Deliv; 2016 Oct; 23(8):2827-2837. PubMed ID: 26548664
[TBL] [Abstract][Full Text] [Related]
4. Simple and efficient liposomal encapsulation of topotecan by ammonium sulfate gradient: stability, pharmacokinetic and therapeutic evaluation.
Liu JJ; Hong RL; Cheng WF; Hong K; Chang FH; Tseng YL
Anticancer Drugs; 2002 Aug; 13(7):709-17. PubMed ID: 12187327
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo studies of different liposomes containing topotecan.
Hao YL; Deng YJ; Chen Y; Wang XM; Zhong HJ; Suo XB
Arch Pharm Res; 2005 May; 28(5):626-35. PubMed ID: 15974453
[TBL] [Abstract][Full Text] [Related]
6. Accelerated blood clearance of pegylated liposomal topotecan: influence of polyethylene glycol grafting density and animal species.
Li C; Cao J; Wang Y; Zhao X; Deng C; Wei N; Yang J; Cui J
J Pharm Sci; 2012 Oct; 101(10):3864-76. PubMed ID: 22777607
[TBL] [Abstract][Full Text] [Related]
7. Development of a highly stable and targetable nanoliposomal formulation of topotecan.
Drummond DC; Noble CO; Guo Z; Hayes ME; Connolly-Ingram C; Gabriel BS; Hann B; Liu B; Park JW; Hong K; Benz CC; Marks JD; Kirpotin DB
J Control Release; 2010 Jan; 141(1):13-21. PubMed ID: 19686789
[TBL] [Abstract][Full Text] [Related]
8. Thermosensitive, near-infrared-labeled nanoparticles for topotecan delivery to tumors.
Rosca EV; Wright M; Gonitel R; Gedroyc W; Miller AD; Thanou M
Mol Pharm; 2015 May; 12(5):1335-46. PubMed ID: 25826624
[TBL] [Abstract][Full Text] [Related]
9. Prolongation of time interval between doses could eliminate accelerated blood clearance phenomenon induced by pegylated liposomal topotecan.
Li C; Zhao X; Wang Y; Yang H; Li H; Li H; Tian W; Yang J; Cui J
Int J Pharm; 2013 Feb; 443(1-2):17-25. PubMed ID: 23318366
[TBL] [Abstract][Full Text] [Related]
10. Development of topotecan loaded lipid nanoparticles for chemical stabilization and prolonged release.
Souza LG; Silva EJ; Martins AL; Mota MF; Braga RC; Lima EM; Valadares MC; Taveira SF; Marreto RN
Eur J Pharm Biopharm; 2011 Sep; 79(1):189-96. PubMed ID: 21352915
[TBL] [Abstract][Full Text] [Related]
11. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
Li C; Wang C; Yang H; Zhao X; Wei N; Cui J
J Pharm Pharmacol; 2012 Mar; 64(3):372-82. PubMed ID: 22309269
[TBL] [Abstract][Full Text] [Related]
12. Liposomal drug delivery systems: from concept to clinical applications.
Allen TM; Cullis PR
Adv Drug Deliv Rev; 2013 Jan; 65(1):36-48. PubMed ID: 23036225
[TBL] [Abstract][Full Text] [Related]
13. The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats.
Dadashzadeh S; Vali AM; Rezaie M
Int J Pharm; 2008 Apr; 353(1-2):251-9. PubMed ID: 18191511
[TBL] [Abstract][Full Text] [Related]
14. Ion-Pairing Contribution to the Liposomal Transport of Topotecan as Revealed by Mechanistic Modeling.
Fugit KD; Anderson BD
J Pharm Sci; 2017 Apr; 106(4):1149-1161. PubMed ID: 28007561
[TBL] [Abstract][Full Text] [Related]
15. Characterization of PEGylated nanoliposomes co-remotely loaded with topotecan and vincristine: relating structure and pharmacokinetics to therapeutic efficacy.
Zucker D; Andriyanov AV; Steiner A; Raviv U; Barenholz Y
J Control Release; 2012 Jun; 160(2):281-9. PubMed ID: 22019556
[TBL] [Abstract][Full Text] [Related]
16. Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model.
Saito R; Krauze MT; Noble CO; Drummond DC; Kirpotin DB; Berger MS; Park JW; Bankiewicz KS
Neuro Oncol; 2006 Jul; 8(3):205-14. PubMed ID: 16723630
[TBL] [Abstract][Full Text] [Related]
17. Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models.
Tardi P; Choice E; Masin D; Redelmeier T; Bally M; Madden TD
Cancer Res; 2000 Jul; 60(13):3389-93. PubMed ID: 10910044
[TBL] [Abstract][Full Text] [Related]
18. Synchronized Ratiometric Codelivery of Metformin and Topotecan through Engineered Nanocarrier Facilitates In Vivo Synergistic Precision Levels at Tumor Site.
Banala VT; Sharma S; Barnwal P; Urandur S; Shukla RP; Ahmad N; Mittapelly N; Pandey G; Dwivedi M; Kalleti N; Mitra K; Rath SK; Trivedi R; Mishra PR
Adv Healthc Mater; 2018 Oct; 7(19):e1800300. PubMed ID: 30102470
[TBL] [Abstract][Full Text] [Related]
19. A Novel Polymer-Lipid Hybrid Nanoparticle for the Improvement of Topotecan Hydrochloride Physicochemical Properties.
Silva EJ; Souza LG; Silva LAD; Taveira SF; Guilger RC; Liao LM; Queiroz Junior LHK; Santana MJ; Marreto RN
Curr Drug Deliv; 2018; 15(7):979-986. PubMed ID: 29243576
[TBL] [Abstract][Full Text] [Related]
20. Sustained-release hydrogels of topotecan for retinoblastoma.
Taich P; Moretton MA; Del Sole MJ; Winter U; Bernabeu E; Croxatto JO; Oppezzo J; Williams G; Chantada GL; Chiappetta DA; Schaiquevich P
Colloids Surf B Biointerfaces; 2016 Oct; 146():624-31. PubMed ID: 27429296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]